Fagron N.V.

Transaction in Own Shares • Jun 24, 2013

Waregem (Belgium) / Rotterdam (the Netherlands)¹ , 24 June 2013 – Arseus discloses the information with respect to the acquisition of treasury shares required under Article 207 of the Royal Decree of 30 January 2001 implementing the Belgian Company Code.

Arseus today announces that on 13 June, it acquired 839 treasury shares on NYSE Euronext Brussels (through an intermediate, acting with a discretionary mandate).

Acquisition date	Number of shares	Average price	Lowest price	Highest price	Amount
13 June 2013	839	€ 19.9953	€ 19.93	€ 20.00	€ 16,776

The Extraordinary Shareholders' Meeting held on 16 June 2009 renewed the authorisation of the Board of Directors to acquire treasury shares.

Prior to the transactions, Arseus held 287,905 treasury shares. As a result of the acquisition of 839 treasury shares, Arseus now holds 288,744 treasury shares.

In the event of any discrepancy between the English translation and the original Dutch version of this press release, the latter shall prevail.

For more information: Constantijn van Rietschoten Director of Corporate Communications +31 88 33 11 222 (Office) +31 6 53 69 15 85 (Mobile) constantijn.van.rietschoten@arseus.com

¹ This press release was sent out by Arseus NV and Arseus BV.

Arseus profile

Arseus is a multinational group of companies that supplies products, services and concepts to professionals and institutions in the healthcare sector in 30 countries worldwide. Arseus is subdivided into four divisions and operates in the markets for pharmaceutical compounding for pharmacies, dental products, medical and surgical products, and medical ICT-solutions. The Belgian company Arseus NV is located in Waregem, and is listed on NYSE Euronext Brussels and NYSE Euronext Amsterdam. The operational activities of the Arseus group are driven by the Dutch company Arseus BV. The head office of Arseus BV is located in Rotterdam.